Latest Articles and Analysis

HIV care system deterioration from administrative obstruction and funding delays presages catastrophic effects of potential budget cuts.

Federal policy changes including Medicaid work requirements and ADAP eligibility restrictions threaten access to HIV medications.

Senate HELP Committee hearing reveals how 340B drug program expansion reflects hospital business strategy rather than patient benefit.

Q4 2025 Watch monitoring HCV treatment access and federal initiatives including Cure Hepatitis C Act.

Clade I mpox emergence reveals structural collapse in U.S. disease surveillance and public health response infrastructure.

Miss Major Griffin-Gracy's legacy demonstrates solidarity's power in building healthcare justice and community leadership.

Government shutdown disrupts grant payments to community health centers and crisis service providers, threatening vulnerable population access.

Deteriorating healthcare infrastructure and provider shortages exacerbate rising rates of sexually transmitted infections.

European price controls demonstrate MFN policy risks: delayed access, treatment rationing, and pharmaceutical innovation collapse.

September government shutdown threatens healthcare systems during November open enrollment, risking coverage loss for 22 million Americans.

Congressional Budget Office confirms 340B program expansion driven by hospital exploitation rather than pharmaceutical price inflation.

RFK Jr's dismantling of CDC scientific leadership replaces expertise with anti-vaccine ideology and predetermined policy conclusions.

Trump administration's revocation of competition executive order accelerates healthcare consolidation and threatens patient access.

Most Favored Nation pricing threatens to import restrictive QALY-based frameworks that discriminate against expensive treatments.

HRSA clarifies 340B eligibility for STI clinics while manufacturers challenge Ryan White program participation.

HRSA's 340B pilot program replicates existing successful models rather than addressing structural program exploitation.

Proposed PEPFAR defunding would eliminate the world's most successful global HIV program and damage international health capacity.

Q3 2025 Watch: critical analysis including Cure Hepatitis C Act proposing subscription treatment models.

Expiration of enhanced ACA subsidies threatens to increase premiums 75% and reduce marketplace enrollment by millions.

340B program expansion drains billions from state Medicaid budgets while failing to deliver promised drug cost savings.